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Statistical Properties of a Two-Stage Model
of Carcinogenesis
by Christopher J. Portier*
Some of the statistical properties of a simple two-stage model of carcinogenesis are explored. The
implications of additive treatment effects versus independent treatment effects on the shape of the dose-
response curve are considered. Response that is low-dose linear results in the cases where the mutation
rates are affected by dose or in the cases where treatment changes the birth rate/death rate of initiated
cells in an additive fashion. Independent treatment effects lead to non-low-dose linear response when the
survival ofinitiated cells is affected by treatment. A computer simulation experiment was performed that
examined the ability of animal carcinogenesis data to differentiate between various forms of this simple
two-stage model. It is shown that animal carcinogenicity experiments do not contain enough data to
adequately describe the difference between these two types of effects.
Introduction
Dose-response models have beenused for many years
in the quantitative analysis of animal carcinogenesis
data. A review of some of the earliest models is given
by Krewski and Brown (1). Recent developments in the
areas of cell biology, biochemistry, molecular biology,
etc., have led to more complicated mechanistic models
of carcinogenesis. These mechanistic models have sev-
eral advantages over simpler probability models or tol-
erance distribution models. As these models utilize
knowledge ofthecarcinogenic process, theyaidindevel-
oping improved testing procedures and in explaining a
broad range of experimental outcomes. Also, these
models generally utilize parameters that have some
typeofmechanisticinterpretation (e.g., mutation rates)
and information on these parameters may be available
from experiments otherthanthe usual long-term chron-
ic bioassay. These models also have their limitations.
Many of these mechanistic parameters are difficult to
obtain, requiring specialized biochemical procedures
that must be developed for each compound. Wheninfor-
mation from experiments other than the typical carcin-
ogenicity experiment is available, the inclusion of this
information into the risk estimation process is difficult,
requiring assumptions that may have questionable bio-
logical applicability.
One mechanistic model of carcinogenesis is the mul-
tistage model (2-4). The original form ofthis model has
been modified to encompass changes in our understand-
ing of the carcinogenic process (3,5,6). An excellent
review ofthe mathematical development ofthe multis-
tage model of carcinogenesis is given by Whittemore
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and Keller (4). In what follows, avery simple two-stage
model of carcinogenesis is studied. Two issues will be
discussed: the shape of dose-response curves derived
from this simple two-stage model and the ability ofani-
mal carcinogenicity data to differentiate between the
different shapes.
Clonal Two-Stage Model
The evidence that carcinogenesis is a multistage pro-
cess is derived from several sources (2,5,7-9). A simple
description ofthisprocess isgivenbythefollowingclon-
al two-stage model. It is believed that in many cases,
the first stage ofthe carcinogenic process is a mutation
(10-12). This collection ofmutated or initiated cells are
allowed to clonally expand by incorporating birth rates
and death rates for these cells. Finally, this two-stage
model requires a second mutation to transform these
initiated cells into malignant cells.
Figure 1 illustrates the compartments of this model
and displays the notation we will use for the rates dis-
cussed above. The birth and deathratesfornormalcells
are denoted by Po and 50, respectively. Let p, denote
the mutation rate ofnormalcellsintoinitiated cells. The
parameters ,13 and 81 representthe birth rate and death
rateofinitiated cells. Finally, let P2denotethemutation
rate of initiated cells into malignant cells. The model
assumes all six ofthese rates are constant with respect
to time. For mathematical simplicity, it is also assumed
that Io = 5o, which is consistent with the assumption
that the number of normal cells is constant over time
and isnotaffectedbytreatmentlevel. Itshouldbenoted
that normal cells still die and divide. The implications
ofvarying the size ofthe population ofnormal cells will
be discussed in the last section ofthis paper.C. J. PORTIER.
FIGURE 1. A simple clonal two-stage model.
Let X denote the equilibrium number ofnormal cells
in the tissue being studied, and let Z(t;d) denote the
number ofmalignant cells at time t in animals receiving
dose dofthe compound beingstudied. In general, there
is a latency period or progression stage from the birth
ofa malignant cell until tumor detection. This progres-
sion could itselfbe a stochastic ordeterministic process,
possibly related to treatment. For the arguments pre-
sented below, it is only necessary that the progression
stage be independent of treatment. Since it is unlikely
that various reasonable choices for the form ofthis pro-
gression would have a serious impact on the results, we
have chosen the simplest progression model, rapid de-
velopment ofatumor. Iftreatmentaffectsthetimefrom
malignant cell formation to tumor detection, results
other than those presented here could result.
Withthese assumptions, ourobjective is tomodelthe
probability of at least one malignant cell as a function
of both time and dose. For untreated animals, this is
given by Moolgavkar (13) as:
Pr[Z(t,O) ¢ 1] =
- [RovL,Fexp[p31
- 8)t]- 1 -(I31
-81)t
The three parameters Ro, ,ul, and X enter into the
model (Eq. 1) as a product which will be denoted by w0.
Itispossiblethat,uocouldbeincreasedand tL decreased
in such a way that the probability expressed by Equa-
tion 1 would not change. In mathematical terminology,
this means that the parameters Ro, ,u1, and X are non-
identifiable from a single experiment. The only identi-
fiable quantity is their product. Thus, from an animal
carcinogenicity experiment, we could estimate w0, but
we could not separate this estimate into its component
parts ,uo, ,ul, and X without further information ob-
tained from other sources. Similarly, yo = P - 81 is
identifiable, but ,13 and 81 are not. Thus, when fitting
animal carcinogenicity data to this model, we can only
estimate the two parameters wo and yo and must use
additional data to estimate the full set of five parame-
ters. This presents two additional problems which must
be considered when interpreting the results. In many
cases, parameters derived from othersources are based
upon an educated guess. Second, when one uses infor-
mation from multiple experiments, care must be taken
to include the uncertainty of this information into the
model.
Incorporating Dose Effects
Risk assessment is a problem ofassessing treatment
effects. There are numerous ways in which dose can
enter into a model of this type. The simplest way of
incorporating dose into this model is to assume a pro-
portional effect of dose on the two parameters -yo and
wo in either an independent or an additive manner.
In this situation, the term additive is used to indicate
that treatment augments an ongoing process. Thus, if
treatment induced a proportional increase in either of
the two mutation rates in this model, the single param-
eter w, which will be referred to as the mutation rate,
would be expressed using two parameters in the form
wo + w1d where d represents the treatment level. Sim-
ilarly, if treatment caused a proportional change in
either the birth rate or the death rate ofinitiated cells,
the model would be modified to include the form
yo + -yld. Note that it is not possible to determine
whether treatment affects the first mutation orthe sec-
ond when the exposure is overthe entire lifetime ofthe
animal. Similarly, iftreatment affects the rate ofbirth
and/or death of initiated cells, it is not possible to de-
termine whether that effect is on the birth rate, the
death rate orboth. This additive clonaltwo-stage model
is given by:
P4Z(t,d) 1] = 1 - exp
F-(exo + p[yd) p[0y + yld)t
- 1 - (yo + -yd)t]]
L - (W~ + (01d) (-yo + -yld)2 [2])
To simplify the notation later, define
S[tldYWO,W1Y,yOy1] = 1 - Pr[Z(t,d) ¢ 1].
Figure 2 illustrates the behavior of this model as a
function of both dose and time. The parameter values
for this example are w0 = 8.55 x 10-7, w, = 3wo,
yo = 0.041, and -Yl = 0. These parameters were derived
fromfitting this clonal two-stage model to the historical
control data for female Fischer 344 rats (14). Since
-Yl = 0, Figure 2 illustrates a situation in which the
treatment only affects the mutation rates. In terminol-
ogy used by several authors (13,15,16), agents that act
in this manner would be labeled as "initiators." Figure
3illustratesthedose-response curveforthismodelafter
2 years of exposure. Similarly, letting 0w = 0 and
,Yl = lyJ2, the dose-response curve at 2 years is altered
as shown in Figure 4. An agent that acts inthis manner
has been referred to as a "promoter." The major dif-
ference between Figure 3 and Figure 4 is in the degree
of curvature of the dose-response relationship; Figure
3 more closely agrees with a linear function than does
Figure 4.

















FIGURE 3. Dose response at 104 weeks for an initiator using an addi-
tive treatment effect.
A major concern in carcinogenic risk assessment is
whether or not a model is low-dose linear. This term is
somewhat misused because it is quite easy to show that
any continuous function canbe approximated by alinear
function in a specified small range. What is meant by
low-dose linear is that the slope of the dose-response
curve at d = 0 is greater than zero. If the slope of the
dose-response curve is greater than zero at d = 0, a
small increase in dose will result in a proportional
increase in risk. On the other hand, if the slope of the
dose-response curve at d = 0 is zero, then a small
increase in dose willresult in virtually no change inrisk.
Forthis reason, dose-response modelsthat arelow-dose
linear generally estimate smaller acceptable exposures







FIGURE 4. Dose response at 104 weeks for a promoter using an addi-
tive treatment effect.
Both ofthe models shown in Figures 3 and 4 are low-
doselinear. Infact, itiseasytoshowthatifspontaneous
tumors exist, the modelgiven in Equation 2 willbe low-
dose linear. Thus, additive treatment effects that are
proportional to dose will result in low-dose linear
models.
Independent treatment effects refer to the situation
in which treatment results in an entirely new carcino-
genic mechanism or modifies a process that protects
against carcinogenesis. Examples of independent
effects would include the development ofunusual muta-
tions, certain types of cytotoxicity, and increased sur-
vival ofinitiated cells thatusually die veryrapidly. Fig-
ure 5 illustrates one situation for which independent
treatment effects might arise. In this example, there
are two paths to carcinogenesis; the top path has a pos-
itive mutation rate and apositive birthrate forinitiated
cells, resulting in spontaneous tumors. The bottompath
has a low mutation rate and a high death rate for ini-
tiated cells, resultingin no spontaneous carcinogenesis.
An independent treatment effect would only affect the
bottom path in this simple example.
To encompass this modelitis necessaryto extend the
notation to include a second subscript. Thus, let wo
denote the mutation parameter in the first (top) path.
Similarly define the remaining parameters as yol, (')02,
012, Y02, and Y12, where the second subscript denotes
thepathtowhichtheparameterapplies. Notethatsince
treatment does not affect the top path, it is assumed
that o1 = 0 and Yii = 0 and are not included in the list
above. Define Pl(t) = 1 - S[tld,woj1,w1 = 0,yoi,jYy = 0]
(the probability of at least one malignant cell via the
first path) and P2(tld) = 1 - S[tld,w02,o12,YO2,Y12] (the
probability ofat least one malignant cell via the second
path). Sinceitisassumedthatallspontaneousmutations
occur via the first path, Pl(t) > 0 and that
P2(tld = 0) = 0. The probability of at least one malig-
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FIGURE 5. A multipath clonal two-stage model.
0.46
L.
(14) on the incidence ofadrenal pheochromocytomas in
female Fischer 344 rats. In the terninology presented
above, this would represent an initiation effect oftreat-
ment. As is obvious by this graph, this type of effect
results in a low-dose linear model. In Figure 7, w12 iS
set to 0 and 'Y12 = 15, a very strong promotion effect.
It is obvious from this plot that an independent pro-
motion effect results in models which are not low-dose
linear and have a slope of zero at dose = 0.
In general, when the background tumor rate is small
or zero, treatment will affect these models in the same
manner as independent treatment effects. That is, ini-
tiators will appear to be low-dose linear and promoters
will not.
In summary, we see that in most cases, treatment
effects in this two-stage model will exhibit low-dose
linear behavior. This includes the additive treatment
effects described above and any proportional treatment
effects on the mutation rate. The only case for which
this model displayed nonlinear low-dose behavior was
for independent promotional effects.
Utility of Carcinogenesis Data for
Determining Mechanism
Theresults ofanimalcarcinogenicity experiments are
used to assess the risk from exposure to environmental
agents (17). To illustrate additional problems with the
use of this model, computer simulation of animal car-
cinogenicity data can be used. The technical details con-
cerning the way in which animal carcinogenicity exper-
iments are simulated has been presented elsewhere
(18). Effectively, the procedure is as follows. First, a
designis chosenthatdeterminesthe dosesandthenum-
ber ofanimals per dose. The simulations that follow use





FIGURE 6. Dose response at 104 weeks for an initiator using an inde-
pendent treatment effect.
nant cell via either path is given by
P(tId) = 1 - (1 - P1(t))(1 - P2(tld)).
Figure 6 illustrates this model at 104 weeks using
parameter values given by wo, = 1.15 x 10-,
Yoi = 4.72, (I)02 = 0.001, )12 = 3.0, Y02 = 4.0, and
Y12 = 0. The parameters wo, and Yo, are derived from
fittingthe two-stage model to the historical control data
0
Dose
FIGURE 7. Dose response at 104 weeks for a promoter using an inde-
pendent treatment effect.
1.0
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of 0.0, 0.25, 0.50, and 1.0. All animals alive at the end
of 2 years are sacrificed. Values are chosen for the
parameters in the clonal two-stage model andfor amod-
el of general survival (19). These parameters are used
to determine the probability of survival and the prob-
ability of one or more malignant cells for each time and
foreach dose group based uponthe equations presented
earlier. Randomnumbers areused todeterminerandom
death times and to decide if a malignancy is present at
that death time or not. After repeating this procedure
for 200 animals (50 per group for 4 groups), an animal
carcinogenicity experiment has been simulated with an
underlying time-dose-response relationship determined
by the clonal two-stage model and the survival model.
It has been suggested thatthe clonal two-stage model
applied to animal carcinogenesis data could be used to
make suggestions aboutthemechanismofactionofsome
carcinogens (13,15,16). Judging from Figures 3 and 4,
it seems unlikely that we would be able to differentiate
between additive initiation and promotion effects when
background response exists. Simulation experiments
provide a means to determine if the ability to differ-
entiate between various mechanisms is possible. Basi-
cally, data are generated from either a promotion-only
model or aninitiation-onlymodel. Whenfittingthismod-
el to simulated carcinogenicity data, it is possible to get
smallpromotional effects inthe experimental range that
have no impact in the low-dose range and vice-versa for
initiation effects. To allow for this, the definition of an
initiator was modified to include all cases where w, dom-
inates the estimate ofadded risk in the low-dose range
even though yi may be positive (see Appendix). Simi-
larly, the definition of a promoter was modified to allow
for the added risk estimate to be dominated by the
estimate of -Yl in the low-dose range. Two other out-
comes are possible in the simulations; no significantly
increaseddose response and significantlyincreased dose
response, which results in both w, and yj affecting the
estimated low-dose risk.
Table 1 shows the percentage of times in 1000 sim-
ulated data sets that an initiator is correctly classified.
For this table, data were generated assuming an addi-
tive treatment effect on wo and assuming -Yl = 0. As the
slope of the dose-response curve increases (column 1),
our ability to correctly classify initiators improves.
However, it is clear from Table 1 that animal carcino-
genesis data does not provide enough information to
correctly classify initiators, with the possible exception
of very steep dose-response curves (w1/wo = 3). When
data are generated using an additive promotion effect,
Table 1. Classification of simulation outcomes for cases where
the chemical is an initiator and treatment effects are additive.
wl/w0 % Initiators % Promoters % Both % Considered
0 29.7 16.2 54.1 3.7
0.5 31.5 26.2 42.3 13.0
1 26.7 33.3 40.0 36.3
2 40.0 26.7 33.3 82.1
3 56.8 20.7 22.5 98.0
atable similarto Table 1 results, withpromotion effects
being correctly classified about 60% ofthe time for the
steepest dose-response modelconsidered. Thus, wefind
that when treatment effects are additive, we cannot
differentiate between initiation effects and promotion
effects.
As mentioned earlier, one advantage of mechanistic
models is that some parameters may be available from
sources otherthanthe cancerbioassay. Assumingthese
parameters are for untreated animals, we see from
Tables 2 and 3 that knowledge ofone ofthe spontaneous
model parameters does not improve our ability to dif-
ferentiate between initiation effects and promotion
effects.
Whenthebackground tumorrate is greaterthanzero
and treatment effects are independent, the ability to
differentiate between initiation effects and promotion
effects is not improved. In Table 4, we have generated
experiments forwhichthere is only apromotional effect
(Y12 > 0, W12 = 0) using the independent treatment
effect model described above. It is clearthat evenwhen
the promotion effect is very strong, there is a chance
that a small initiation effect will dominate the low-dose
risk estimates. Again, as is illustrated by Table 5,
knowledge of one of the spontaneous parameters does
not noticeably improve the ability of animal carcino-
genesis data to differentiate between promoters and
initiators.
The examples presented above are for the cases
Table 2. Classification of simulation outcomes for cases where
the chemical is an initiator, treatment effects are additive, and
w is known without error.
wl/wo % Initiators % Promoters % Both % Considered
0 7.7 30.8 61.5 2.6
0.5 15.8 31.5 52.7 12.7
1 23.2 32.7 44.1 36.7
2 41.9 26.9 31.2 82.3
3 56.4 20.9 22.7 98.3
Table 3. Classification of simulation outcomes for cases where
the chemical is an initiator, treatment effects are additive, and
yo is known without error.
w,/wo % Initiators % Promoters % Both % Considered
0 11.1 25.9 63.0 2.7
0.5 19.2 29.6 51.2 12.5
1 26.3 33.1 40.6 35.7
2 41.5 26.8 31.7 82.2
3 56.6 20.7 22.7 98.0
Table 4. Classification of simulation outcomes for cases where
the chemical is a promoter and treatment effects are
independent.
Y12 % Initiators % Promoters % Both % Considered
0 82.4 11.8 5.8 1.7
10 77.8 16.7 5.5 1.8
12 77.5 22.5 0.0 4.0
14 51.8 47.0 1.2 32.8
17 37.4 60.0 2.6 99.9
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Table 5. Classification of simulation outcomes for cases where
the chemical is a promoter, treatment effects are independent,
and wo, is known without error.
Y12 % Initiators % Promoters % Both % Considered
0 88.9 11.1 0.0 1.8
10 78.9 21.1 0.0 1.9
12 68.6 28.6 2.8 3.5
14 48.9 50.2 0.9 32.7
17 35.6 62.6 1.8 100.0
where there exists a background tumor response. For
the case ofvery small or zero background response, the
ability todifferentiate between initiators andpromoters
improvesconsiderably, approachingperfectionforsteep
dose-response curves. Note also that we are discussing
low-dose initiation versus low-dose promotion. Chang-
ing the definition of "low dose" and modifying the def-
initions of "initiators" and "promoters" could obviously
alter the results ofthis analysis.
Finally, to show how random chance can lead to an
incorrectinterpretationofbioassayresults, considerthe
estimated model shown in Figure 8. Curves with this
shape occurred in 0.5 to 2% of the simulations. If one
were to estimate this model from animal carcinogenesis
data, one would conclude that the chemical is highly
mutagenic at low doses and highly cytotoxic to initiated
cells at high doses. However, this is simply the reali-
zation of a random event from a model which in truth
looks nothing like this model. Thus, one should be very
careful in interpreting the results of curve fitting when
using a model as flexible as this one.
Summary
This manuscript has discussed two topics concerning









FIGURE 8. Dose-response at 104 weeks for a sample data set that
suggests the compound is an initiator and toxic to initiated cells.
sessment. The first problem concerns the incorporation
oftreatment effects into the model. It was shown that
iftreatmententersintothemodelinanadditivefashion,
then the model will behave in a low-dose linear fashion.
If, on the other hand, background response is near zero
or treatment can be incorporated in an independent
fashion, it may be possible to have nonlinear low-dose
risk. The second issue concerns the ability of animal
carcinogenesis datatodifferentiate between alternative
mechanisms ofcarcinogenesis. Inthis case it was shown
that it is not possible to differentiate between mecha-
nisms for a very simple two-stage model.
The two-stage model considered in this study did not
allow for changes in the size of the susceptible normal
population. Hormonal changes in the animals could re-
sult in age-related changes in the size ofthe susceptible
population (20,21). Itis also possible that the treatment
could be cytotoxic, reducing the size ofthe susceptible
population and/or increasing the mitotic rate in these
cells. It is possible that these mechanisms could play a
significant role in the formation of tumors. In general
it is believed these mechanisms would result in dose-
response relationships that will not be low-dose linear.
As is the case above, this will depend upon whether
they are proportional effects and whether these effects
are independent or additive.
Despite the problems mentioned above, mechanistic
models serve an important role in carcinogenic risk as-
sessment. When one is extrapolating beyond the range
ofthe data, one would like to use a model that contains
the largest amount ofinformation available on the pro-
cess being modeled. In addition, these models are very
useful for developing alternative designs and novel ex-
periments to address broader issues in cancer risk as-
sessment. They also provide a conceptual framework in
which to think about experimental results and help to
combine information from a variety of experiments.
However, one should be carefulnotto overinterpretthe
parameters arrived at by fitting mechanistic models to
animal data.
APPENDIX
As mentioned in the text, the definitions ofinitiators
and promoters were modified for dealing with model
estimates fromthe simulations. Forthe purposesofrisk
assessment it is too strict to require that estimated
parameters be identicallyzero before aclassification can
be made. Instead, since low-dose risk assessment is the
goal of our analysis, the definition was modified so that
a simulated response was labeled as an initiator if the
dose-related mutation parameter (wi) dominated the
low-dose risk estimate. This was done by calculating
the four values Sd = S(1041E, WO, W1, Yo, yl),
Sp = S(1041E, Wo, O)j = 0, Yo, yj), Si = S(1041E, ('o, 1i
yo, -y = 0), So = S(1041E, o, (i = 0, -Yo, -Y1 = 0) for
E = i0-5. The value ofSO - Sd estimates the added risk
of tumor from exposure to a dose E of the simulated
chemical. Since Sp uses w, = 0, then SO - Sp estimates
the added risk from exposure to adose E whenthe dose-
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related mutation parameter is set to zero (without esti-
mating the remaining parameters again). IfSO - Sp is
close in value to SO - Sd, then one could conclude that
the promotion effect is very strong at low doses. Sim-
ilarly, SO - Si estimates the added risk for a dose of E
using only the initiation effect. A simulated effect was
considered to be a low dose initiation effect if(SO - Si)l
(So - Sd) - (So - Sp)/(S0 - Sd) >0.10. That is, the rel-
ative initiation effect is 10% larger than the relative
promotion effect. Similarly, if this quantity was less
than -0.10, the simulated effect was assumed to be a
promotion effect. Since, forvery lowdoses, smallmuta-
tion effects could dominate the added risk estimate, we
also considered E = 0.01. The results in Tables 1-3 are
forE = 10' and those in Tables4 and 5areforE = 0.01.
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